A comprehensive view of epidemic/pandemic. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Sustainability & Social Responsibility Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Pfizer responds to accusations about its alleged manipulation of Covid virus to create new vaccines, stating it has not conducted gain-of-function or targeted evolution research; company acknowledges it has conducted research on original Sars-CoV-2 virus
Published: January 31, 2023 by CE Noticias Financieras (Latin America)
Pfizer first pharmaceutical company with over US$100.0B in sales, reporting sales of US$100.33B in 2022; profits increased 43% year-over-year to US$31.4B, more than triple the profits in 2020
Published: January 31, 2023 by CE Noticias Financieras (Latin America)
Pfizer expects COVID-19 vaccine and Paxlovid pill revenues will fall 60% in 2023 to US$21.5B; Pfizer estimated COVID-19 vaccine demand will drop 29% to about 65 million doses this year due to end of government funding for the shot
Published: January 31, 2023 by Forbes
Moderna expands partnership with Swiss biopharma CDMO Lonza to increase production of COVID-19 vaccine drug substances; Lonza to add new manufacturing line at Geleen, Netherlands, plant with capacity to add up 300 million doses per year
Published: January 30, 2023 by Chemical Weekly (CBNB Abstracts)
Sales forecasts for Pfizer’s Paxlovid may change due to easing of Chinese zero-COVID policy, which could surge infection rate, increase Paxlovid demand; Pfizer has distributed millions of Paxlovid treatments in China since policy change
Published: January 30, 2023 by International Business Times

Ask us about our Sustainability & Social Responsibility market view

Trending Chart

Interactive chart with headline count